Tianjin Pharmaceutical receives China approval for dexamethasone API

November 20, 2026  Source: drugdu 36

"/
On November 19, Tianjin Pharmaceutical (600488) disclosed that China’s National Medical Products Administration had approved its marketing application for dexamethasone active pharmaceutical ingredient (API). Dexamethasone has antiallergic, antipyretic and immunosuppressive properties and is used primarily for allergic and autoimmune inflammatory diseases.
The article lists marketed Chinese dosage forms including single-ingredient dexamethasone tablets and combination products in eye drops, ophthalmic ointments, topical ointments and injections.

Source: http://finance.eastmoney.com/a/202611193935031069.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.